Overview:<\/strong> Zonisamide is a sulfonamide antiseizure medicine supplied as oral capsules and, in some markets, a separately labelled suspension. The reviewed US generic capsule label covers add-on treatment of partial seizures in adults. The UK Zonegran label also includes adult monotherapy and add-on treatment from age six. A different country label does not establish US approval for those additional uses.<\/p>\n Uses and formulation:<\/strong> Treatment is adjusted gradually according to seizure control, tolerability and organ function. Capsules should be swallowed whole and may be taken with or without food. Do not switch formulations, change another antiseizure medicine or stop zonisamide suddenly on your own. Abrupt withdrawal can worsen seizures, and the appropriate taper depends on the whole treatment plan.<\/p>\n Safety:<\/strong> Seek prompt help for a spreading or blistering rash, fever with facial swelling, sudden eye pain, markedly reduced sweating in hot weather, or unexplained confusion and vomiting. Important monitored risks include metabolic acidosis, kidney stones and hyperammonemia. Sleepiness, appetite loss, dizziness and memory or concentration difficulties are more common effects. Pregnancy and breastfeeding need specialist assessment because fetal risk and milk transfer are relevant.<\/p>\n Drug interactions:<\/strong> Topiramate and acetazolamide can add to carbonic anhydrase inhibition. Valproate and topiramate may increase hyperammonemia risk. Enzyme-inducing medicines can lower zonisamide exposure, especially when introduced, withdrawn or changed. Other sedating or anticholinergic medicines need a review for cognitive impairment or overheating. A theoretical digoxin interaction requires caution; it should not be described as proven toxicity in every patient.<\/p>\nSources<\/h2>\n